SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

Truist Securities Maintains Buy on Concert Pharma, Raises Price Target to $25

Truist Securities analyst Joon Lee maintains Concert Pharma (NASDAQ:CNCE) with a Buy and raises the price target from $22 to $25.

Benzinga · 09/13/2022 09:35
Truist Securities analyst Joon Lee maintains Concert Pharma (NASDAQ:CNCE) with a Buy and raises the price target from $22 to $25.